TGTX
TG THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$53.30
−1.24%Year over year
Reported trailing growth
- Revenue
- +76.1%
- EBITDA
- +37.4%
- EBIT
- +58.8%
- EPS
- +634.6%
- Free cash flow
- +129.3%
- Operating cash flow
- +130.2%
Forward estimates
Based on analyst estimates
- Revenue
- +49.8%
- EBITDA
- +271.7%
- EPS
- -24.9%
Three-year CAGR
- Revenue
- +504.9%
- EBITDA
- +126.9%
- EBIT
- +144.5%
- Net income
- +494.0%
- EPS
- +489.2%
- Free cash flow
- +38.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026